

## DAFTAR PUSTAKA

- Agbo, M. C., Ezeonu, I. M., Odo, M. N., Ononugbo, C. M., Onodagu, B. O., Eze, C. C., ... & Ozioko, C. A. (2019). Phenotypic and molecular characterization of extended spectrum-lactamase producing *Pseudomonas aeruginosa* in Nigeria. *African Journal of Biotechnology*, 18(32), 1083-1090.
- Ahmed, O. B., & Asghar, A. H. (2017). Antibiotic susceptibility pattern of *Pseudomonas aeruginosa* expressing blaGES and blaPER genes in two different hospitals. *African Journal of Biotechnology*, 16(21), 1197-1202.
- Alikhani, M. Y., Tabar, Z. K., Mihani, F., Kalantar, E., Karami, P., Sadeghi, M., ... & Farajnia, S. (2014). Antimicrobial resistance patterns and prevalence of blaPER-1 and blaVEB-1 genes among ESBL-producing *Pseudomonas aeruginosa* isolates in West of Iran. *Jundishapur Journal of Microbiology*, 7(1).
- Ambler, R. P. (1980). The structure of  $\beta$ -lactamases. *Philosophical Transactions of the Royal Society of London. B, Biological Sciences*, 289(1036), 321-331.
- Amirkamali, S., Naserpour-Farivar, T., Azarhoosh, K., & Peymani, A. (2017). Distribution of the bla OXA, bla VEB-1, and bla GES-1 genes and resistance patterns of ESBL-producing *Pseudomonas aeruginosa* isolated from hospitals in Tehran and Qazvin, Iran. *Revista da Sociedade Brasileira de Medicina Tropical*, 50(3), 315-320.
- Anggraini, D., Yulindra, U. G., Savira, M., Djojosingito, F. A., & Hidayat, N. (2018). Prevalensi dan Pola Sensitivitas Antimikroba Multidrug Resistant *Pseudomonas aeruginosa* di RSUD Arifin Achmad. *Majalah Kedokteran Bandung*, 50(1), 6-12.
- Anollés, C. (2013). Polymerase chain reaction. *Elsevier*, 392-395.
- Azimi, S., Kafil, H. S., Baghi, H. B., Shokrian, S., Najaf, K., & Asgharzadeh, M. (2016). Presence of exoY, exoS, exoU and exoT genes, antibiotic resistance and biofilm production among *Pseudomonas aeruginosa* isolates in Northwest Iran. *GMS hygiene and infection control*, 11.
- Barie, P. S. (2012). Multidrug-resistant organisms and antibiotic management. *Surgical Clinics*, 92(2), 345-391.
- Bavasheh, N., & Karmostaji, A. (2017). Antibiotic Resistance Pattern and Evaluation of blaOXA-10, blaPER-1, blaVEB, blaSHV Genes in Clinical Isolates of *Pseudomonas aeruginosa* Isolated from Hospital in South of Iran in 2014-2015. *Infection, Epidemiology and Microbiology*, 3(1), 1-5.

- Bbosa, G. S., Mwebaza, N., Odda, J., Kyegombe, D. B., & Ntale, M. (2014). Antibiotics/antibacterial drug use, their marketing and promotion during the post-antibiotic golden age and their role in emergence of bacterial resistance. *Health, 2014*.
- Begum, S., Salam, M. A., Alam, K. F., Begum, N., Hassan, P., & Haq, J. A. (2013). Detection of extended spectrum  $\beta$ -lactamase in *Pseudomonas* spp. isolated from two tertiary care hospitals in Bangladesh. *BMC research notes, 6*(1), 1-4.
- Bradford, P. A. (2001). Extended-spectrum  $\beta$ -lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. *Clinical microbiology reviews, 14*(4), 933-951.
- Brooks, G. F., Carroll, K. C., Butel, J. S., Stephen, M., & Timoty, M. (2004). *Antimicrobial Chemotherapy in Medical Microbiology* (Vol. 23 rd edition): McGraw Hill Companies.
- Bush, K., & Jacoby, G. A. (2010). Updated functional classification of  $\beta$ -lactamases. *Antimicrobial agents and chemotherapy, 54*(3), 969-976.
- Bush, K., Jacoby, G. A., & Medeiros, A. A. (1995). A functional classification scheme for beta-lactamases and its correlation with molecular structure. *Antimicrobial agents and chemotherapy, 39*(6), 1211.
- Chaudhari, V., Gunjal, S., & Mehta, M. (2013). Antibiotic resistance patterns of *Pseudomonas aeruginosa* in a tertiary care hospital in Central India. *Int J Med Sci Public Health, 2*(2), 386-9.
- Chong, Y., Yakushiji, H., Ito, Y., & Kamimura, T. (2011). Clinical and molecular epidemiology of extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in a long-term study from Japan. *European journal of clinical microbiology & infectious diseases, 30*(1), 83-87.
- Cillóniz, C., Gabarrús, A., Ferrer, M., de la Bellacasa, J. P., Rinaudo, M., Mensa, J., ... & Torres, A. (2016). Community-acquired pneumonia due to multidrug-and non-multidrug-resistant *Pseudomonas aeruginosa*. *Chest, 150*(2), 415-425.
- CLSI. (2017). Performance standards for antimicrobial susceptibility testing. In: Clinical and Laboratory Standards Institute Wayne, PA.
- Davies, J., & Davies, D. (2010). Origins and evolution of antibiotic resistance. *Microbiology and molecular biology reviews, 74*(3), 417-433.
- Dhillon, R. H.-P., & Clark, J. (2012). ESBLs: a clear and present danger? *Critical care research and practice, 2012*.

- Farshadzadeh, Z., Khosravi, A. D., Alavi, S. M., Parhizgari, N., & Hoveizavi, H. (2014). Spread of extended-spectrum  $\beta$ -lactamase genes of bla OXA-10, bla PER-1 and bla CTX-M in *Pseudomonas aeruginosa* strains isolated from burn patients. *Burns*, *40*(8), 1575-1580.
- Jayanthi, S., & Jeya, M. (2014). Plasmid profile analysis and bla VIM gene detection of metallo  $\beta$ -lactamase (MBL) producing *Pseudomonas aeruginosa* isolates from clinical samples. *Journal of clinical and diagnostic research: JCDR*, *8*(6), DC16.
- Joshi, M., & Deshpande, J. (2010). Polymerase chain reaction: methods, principles and application. *International Journal of Biomedical Research*, *2*(1), 81-97.
- Komijani, M., Shahin, K., Barazandeh, M., & Sajadi, M. (2018). Prevalence of extended-spectrum  $\beta$ -lactamases genes in clinical isolates of *Pseudomonas aeruginosa*. *Medical Laboratory Journal*, *12*(5), 34-41.
- Laudy, A. E., Róg, P., Smolińska-Król, K., Ćmiel, M., & Słoczyńska, A. (2017). Prevalence of ESBL-producing *Pseudomonas aeruginosa* isolates in Warsaw, Poland, detected by various phenotypic and genotypic methods. *PloS one*, *12*(6), e0180121.
- Lee, S., Park, Y.-J., Kim, M., Lee, H. K., Han, K., Kang, C. S., & Kang, M. W. (2005). Prevalence of Ambler class A and D  $\beta$ -lactamases among clinical isolates of *Pseudomonas aeruginosa* in Korea. *Journal of Antimicrobial Chemotherapy*, *56*(1), 122-127.
- Libisch, B., Poirel, L., Lepsanovic, Z., Mirovic, V., & Balogh, B. (2008). Identification of PER-1 extended-spectrum  $\beta$ -lactamase producing *Pseudomonas aeruginosa* clinical isolates of the international clonal complex CC11 from Hungary and Serbia. *FEMS Immunology & Medical Microbiology*, *54*(3), 330-338.
- Lila, G., Mulliqi, G., Raka, L., Kurti, A., Bajrami, R., & Azizi, E. (2018). Molecular epidemiology of *Pseudomonas aeruginosa* in University clinical center of Kosovo. *Infection and drug resistance*, *11*, 2039.
- Lin, S.-P., Liu, M.-F., Lin, C.-F., & Shi, Z.-Y. (2012). Phenotypic detection and polymerase chain reaction screening of extended-spectrum  $\beta$ -lactamases produced by *Pseudomonas aeruginosa* isolates. *Journal of Microbiology, Immunology and Infection*, *45*(3), 200-207.
- Mehta, A., & Prabhu, T. (2016). Detection and characterization of metallo $\beta$  lactamases producing *Pseudomonas aeruginosa* clinical isolates at a tertiary care hospital of Bhopal, India. *International Journal of Research in Medical Sciences*, *4*(9), 4084.
- Miller, G. H., Sabatelli, F. J., Hare, R. S., Glupczynski, Y., Mackey, P., Shlaes, D., ... & Aminoglycoside Resistance Study Groups. (1997). The

- most frequent aminoglycoside resistance mechanisms—changes with time and geographic area: a reflection of aminoglycoside usage patterns?. *Clinical infectious diseases*, 24(Supplement\_1), S46-S62.
- Mirsalehian, A., Feizabadi, M., Nakhjavani, F. A., Jabalameli, F., Goli, H., & Kalantari, N. (2010). Detection of VEB-1, OXA-10 and PER-1 genotypes in extended-spectrum  $\beta$ -lactamase-producing *Pseudomonas aeruginosa* strains isolated from burn patients. *Burns*, 36(1), 70-74.
- Mittal, R., Aggarwal, S., Sharma, S., Chhibber, S., & Harjai, K. (2009). Urinary tract infections caused by *Pseudomonas aeruginosa*: a minireview. *Journal of infection and public health*, 2(3), 101-111.
- Murray, P. R., Rosenthal, K. S., & Tenover, M. C. (2016). *Antibacterial Agents in Medical Microbiology* (Vol. 8th edition): Elsevier Inc.
- Naas, T., Poirel, L., & Nordmann, P. (2008). Minor extended-spectrum  $\beta$ -lactamases. *Clinical microbiology and infection*, 14, 42-52.
- Nakasone, I., Kinjo, T., Yamane, N., Kisanuki, K., & Shiohira, C. M. (2007). Laboratory-based evaluation of the colorimetric VITEK-2 Compact system for species identification and of the Advanced Expert System for detection of antimicrobial resistances: VITEK-2 Compact system identification and antimicrobial susceptibility testing. 58(2), 191-198.doi:10.1016/j.diagmicrobio.2006.12.008
- Olowe, O., & Adefioye, S. (2014). Understanding extended spectrum betalactamases in clinical settings. Review update. *Int J Med Appl Sci*, 3, 51-61.
- Paterson, D. L., & Bonomo, R. A. (2005). Extended-spectrum  $\beta$ -lactamases: a clinical update. *Clinical microbiology reviews*, 18(4), 657-686.
- Pincus, D. H. (2006). Microbial identification using the bioMérieux Vitek® 2 system. *Encyclopedia of rapid microbiological methods*, 1, 1-32.
- Pobiega, M., Wojkowska-Mach, J., Maciag, J., Chmielarczyk, A., & Romaniszyn, D. (2014). Virulence and antibiotic resistance of *Pseudomonas aeruginosa* isolated from patients with urinary tract infections in Southern Poland. *Chemotherapy*, 60(4), 253-260.
- Poirel, L., Le Thomas, I., Naas, T., Karim, A., & Nordmann, P. (2000). Biochemical sequence analyses of GES-1, a novel class A extended-spectrum  $\beta$ -lactamase, and the class 1 integron In52 from *Klebsiella pneumoniae*. *Antimicrobial agents and chemotherapy*, 44(3), 622-632.
- Rupp, M. E., & Fey, P. D. (2003). Extended spectrum  $\beta$ -lactamase (ESBL)-producing Enterobacteriaceae. *Drugs*, 63(4), 353-365.

- Saha, S., Rahman, S., Hassan, F. N., Sarkar, S., Islam, K., Saha, P., ... & Hasan, S. (2015). Antimicrobial resistance in uropathogen isolates from patients with urinary tract infections. *Biomedical Research and Therapy*, 2(5), 1-7.
- Shaikh, S., Fatima, J., Shakil, S., Rizvi, S. M. D., & Kamal, M. A. (2015). Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment. *Saudi journal of biological sciences*, 22(1), 90-101.
- Shankar, P. R., & Balasubramaniam, R. (2014). Antimicrobial resistance: global report on surveillance 2014. *Australasian Medical Journal (Online)*, 7(5), 237.
- Strateva, T., Ouzounova-Raykova, V., Markova, B., Todorova, A., Marteva-Proevska, Y., & Mitov, I. (2007). Problematic clinical isolates of *Pseudomonas aeruginosa* from the university hospitals in Sofia, Bulgaria: current status of antimicrobial resistance and prevailing resistance mechanisms. *Journal of medical microbiology*, 56(7), 956-963.
- Streeter, K., & Katouli, M. (2016). *Pseudomonas aeruginosa: A review of their Pathogenesis and Prevalence in Clinical Settings and the Environment*.
- Tavajjohi, Z., Moniri, R., & Zarrabi, M. (2013). Detection of GES-2, a Class A  $\beta$ -Lactamase Produced by *Pseudomonas aeruginosa* in a Teaching Hospital in Iran. *Jundishapur Journal of Microbiology*, 6(10)
- Tham, J. (2012). *Extended-spectrum beta-lactamase-producing enterobacteriaceae: epidemiology, risk factors, and duration of carriage* (Vol. 2012): Lund University.
- Todar, K. (2011). Bacterial resistance to antibiotics (page 3). *Todar's online textbook of bacteriology*, 4.
- Ullah, F., Malik, S. A., & Ahmed, J. (2009). Antimicrobial susceptibility and ESBL prevalence in *Pseudomonas aeruginosa* isolated from burn patients in the North West of Pakistan. *Burns*, 35(7), 1020-1025.
- WHO, World Health Organization. (2011). *Establishment of PCR laboratory in developing countries*.
- Wu, D. C., Chan, W. W., Metelitsa, A. I., Fiorillo, L., & Lin, A. N. (2011). *Pseudomonas* skin infection. *American journal of clinical dermatology*, 12(3), 157-169.
- Yadav, K. K., Adhikari, N., Khadka, R., Pant, A. D., & Shah, B. (2015). Multidrug resistant Enterobacteriaceae and extended spectrum  $\beta$ -lactamase producing *Escherichia coli*: a cross-sectional study in


National Kidney Center, Nepal. *Antimicrobial resistance and infection control*, 4(1), 42.

Yamano, Y., Nishikawa, T., Fujimura, T., Yutsudou, T., Tsuji, M., & Miwa, H. (2006). Occurrence of PER-1 producing clinical isolates of *Pseudomonas aeruginosa* in Japan and their susceptibility to doripenem. *Journal of Antibiotics*, 59(12), 791.

# LAMPIRAN

## LAMPIRAN 1



### Rekomendasi Persetujuan Etik


 KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN  
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN  
 KOMITE ETIK PENELITIAN KESEHATAN  
 RSPTN UNIVERSITAS HASANUDDIN  
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR  
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu  
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.  
 Contact Person: dr. Agusssalim Bukhari, M.Med.,Ph.D., Sp.GK, TELP. 081241850858 0411 5780103, Fax : 0411 581931
 

---

**REKOMENDASI PERSETUJUAN ETIK**  
 Nomor : 832/UN4.6.4.5.31/ PP36/ 2020  
 Tanggal: 30 Desember 2020

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH20120716		No Sponsor Protokol	
Peneliti Utama	<b>dr. Wahyunita,S.Ked</b>		Sponsor	
Judul Peneliti	Deteksi Gen Resistensi pada Isolat Pseudomonas Aeruginosa dari Pasien di RSUP Dr. Wahidin Sudirohusodo			
No Versi Protokol	<b>1</b>	Tanggal Versi	23 Desember 2020	
No Versi PSP		Tanggal Versi		
Tempat Penelitian	<b>RS Universitas Hasanuddin dan RSUP Dr. Wahidin Sudirohusodo Makassar</b>			
Jenis Review	<input checked="" type="checkbox"/> Exempted	Masa Berlaku	30 Desember 2020 sampai 30 Desember 2021	
	<input type="checkbox"/> Expedited	Frekuensi review	lanjutan	
	<input type="checkbox"/> Fullboard Tanggal			
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama <b>Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)</b>	Tanda tangan		
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama <b>dr. Agusssalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)</b>	Tanda tangan		

Kewajiban Peneliti Utama:

- Menyerahkan Amendemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapo SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

## LAMPIRAN 2

Hasil tes sensitivitas antibiotik pada isolat bakteri *Pseudomonas aeruginosa*

KODE LAB	SPESIMEN	DIAGNOSIS	SENSITIVITAS ANTIBIOTIK							
			CAZ	CTX	IMI	MEM	DORI	AK	GN	TOB
WS 1	Pus	Keganasan	S	R	R	R	R	S	S	S
WS 2	Pus	Kulit	S	R	R	R	R	S	S	S
WS 3	Sputum	Pernapasan	S	R	S	S	S	S	S	S
WS 4	Darah	Saraf	S	-	-	R	-	S	S	-
WS 5	Sputum	Pernapasan	S	-	-	S	-	S	S	-
WS 6	Sputum	-	S	R	S	S	S	S	S	S
WS 7	Pus	-	S	-	-	S	-	S	S	-
WS 8	Pus	Endokrin, Nutrisi, Metabolik	S	R	R	I	R	S	S	S
WS 9	Sputum	Pernapasan	S	R	S	S	S	S	S	S
WS 10	Bilasan Bronchus	Pernapasan	S	-	-	S	-	S	S	-
WS 11	Sputum	Trauma	S	R	S	S	S	S	S	S
WS 12	Pus	Jantung dan Pembuluh Darah	S	R	S	S	S	S	S	S
WS 13	Sputum	-	S	R	S	S	S	S	S	S
WS 14	Pus	Luka Bakar	R	R	R	S	I	S	S	S
WS 15	Cairan Pleura	-	S	R	S	S	S	S	S	S
WS 16	Sputum	Keganasan	S	R	S	S	S	S	S	S
WS 17	Jaringan	-	S	R	S	S	S	S	S	S
WS 18	Jaringan	Pernapasan	S	R	S	S	S	S	S	S
WS 19	Darah	Jantung dan Pembuluh Darah	R	-	-	S	-	S	S	-
WS 20	Pus	-	R	R	S	S	S	S	S	S
WS 21	Pus	Luka Bakar	R	-	-	S	-	S	S	-
WS 22	Urine	Genitourinaria	S	R	S	S	S	S	S	S
WS 23	Pus	Saraf	S	R	S	S	S	S	S	S
WS 24	Pus	Trauma	S	-	-	S	-	S	I	-
WS 25	Sekret Telinga	THT	S	-	-	S	-	S	S	-
WS 26	Pus	Gastroenterohepatologi	S	S	S	S	S	S	S	S
WS 27	Sputum	Sepsis	S	R	R	R	S	S	S	S
WS 28	Pus	Endokrin, Nutrisi, Metabolik	S	R	R	S	S	S	S	S
WS 29	Sputum	Jantung dan Pembuluh Darah	S	-	-	S	S	S	S	-
WS 30	Sputum	Pernapasan	S	-	S	S	S	S	S	-
WS 31	Pus	Saraf	S	R	R	R	R	S	S	S
WS 32	Sputum	-	S	-	-	S	S	S	S	-



WS 33	Sputum	Pernapasan	S	R	S	S	S	S	S	S
WS 34	Sputum	Pernapasan	S	R	S	S	S	S	S	S
WS 35	Pus	Kulit	S	R	S	S	S	S	S	S
WS 36	Sputum	Saraf	S	R	S	S	S	S	S	S
WS 37	Darah	Keganasan	S	R	S	S	S	S	S	S
WS 38	Pus	THT	S	-	-	S	-	S	S	-
WS 39	Bilasan Bronchus	-	R	R	R	I	R	S	S	S
WS 40	Urine	Saraf	I	R	R	R	R	S	I	S
WS 41	Sputum	Pernapasan	S	R	S	S	S	S	S	S
WS 42	Pus	Gastroenterohepatologi	S	R	S	S	S	S	S	S
WS 43	Sputum	-	S	R	S	S	S	S	S	S
WS 44	Bilasan Lambung	Sepsis	S	R	S	S	S	S	S	S
WS 45	Pus	THT	S	R	S	S	S	S	S	S
WS 46	Darah	Genitourinaria	S	R	S	S	S	S	S	S
WS 47	Pus	Luka Bakar	R	R	R	R	R	R	R	S
WS 48	Pus	THT	I	R	S	S	S	S	S	S
WS 49	Pus	Luka Bakar	S	R	R	R	R	R	R	R
WS 50	Pus	Saraf	R	R	I	I	I	S	S	S
WS 51	Sputum	Sepsis	S	R	S	S	S	S	S	S
WS 52	Cairan Asites	Gastroenterohepatologi	S	R	S	S	S	S	S	S
WS 53	Sputum	-	R	R	R	I	I	S	S	S
WS 54	Urine	-	S	R	S	S	S	S	S	S
WS 55	Jaringan	Gastroenterohepatologi	S	R	S	S	S	S	S	S
WS 56	Pus	-	R	R	S	S	S	S	S	S
WS 57	Pus	Gastroenterohepatologi	S	R	S	S	S	S	S	S
WS 58	Sputum	Saraf	R	R	S	S	S	S	S	S
WS 59	Jaringan	Trauma	S	R	S	S	S	S	S	S
WS 60	Jaringan	Endokrin, Nutrisi, Metabolik	S	R	S	S	S	S	S	S
WS 61	Jaringan	Keganasan	S	R	S	S	S	S	S	S
WS 62	Sputum	Pernapasan	S	R	S	S	S	S	S	S
WS 63	Sputum	Genitourinaria	R	R	R	R	R	S	S	R
WS 64	Sputum	Keganasan	S	R	S	S	S	S	S	S
WS 66	Sputum	Darah	R	R	S	S	S	S	S	R
WS 67	Pus	-	I	R	S	S	S	S	R	R
WS 68	Pus	Keganasan	R	R	R	R	R	S	S	S
WS 69	Sekret Telinga	Saraf	R	R	S	S	S	S	S	S
WS 70	Sekret Telinga	Saraf	S	R	S	S	S	S	I	S
WS 71	Sputum	Jantung dan Pembuluh Darah	S	-	-	S	-	S	S	-
WS 73	Pus	Trauma	R	R	R	R	R	R	R	R
WS 74	Sputum	-	R	R	S	S	S	S	S	S
WS 75	Sputum	Saraf	S	R	S	S	S	S	S	S

WS 76	Pus	Keganasan	S	R	S	S	S	S	S	S
WS 77	Sputum	Saraf	R	R	S	S	S	S	S	S
WS 78	Sputum	Saraf	R	R	R	R	R	S	S	S
WS 79	Darah	Keganasan	R	R	S	S	S	S	S	S
WS 80	Sputum	Pernapasan	S	I	S	R	R	S	S	R
WS 81	Pus	Jantung dan Pembuluh Darah	I	R	S	S	S	S	S	S
WS 82	Sputum	Keganasan	S	-	-	S	-	S	S	-
WS 83	Pus	Gastroenterohepatologi	R	-	-	S	-	S	S	-
WS 84	Pus	Saraf	S	-	-	S	-	S	S	-
WS 85	Pus	Kulit	R	R	S	S	S	S	S	S
WS 86	Pus	Darah	R	-	-	R	-	S	S	-
WS 87	Pus	Pernapasan	R	R	S	S	S	S	S	S

### LAMPIRAN 3

Hasil Elektroforesis amplifikasi negatif pada isolat *Pseudomonas aeruginosa*

